-
Je něco špatně v tomto záznamu ?
Cyclomodulins and Hemolysis in E. coli as Potential Low-Cost Non-Invasive Biomarkers for Colorectal Cancer Screening
K. Mezerová, L. Starý, P. Zbořil, I. Klementa, M. Stašek, P. Špička, P. Skalický, V. Raclavský
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
IGA_LF_2021_022
the Faculty of Medicine & Dentistry, Palacký University Olomouc
DRO 61989592
the Ministry of Education, Youth and Sports, Czech Republic
DROFNOl 00098892, NV19-03-00069
the Ministry of Health, Czech Republic
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
PubMed
34833041
DOI
10.3390/life11111165
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
The frequent occurrence of E. coli positive for cyclomodulins such as colibactin (CLB), the cytotoxic necrotizing factor (CNF), and the cytolethal distending factor (CDT) in colorectal cancer (CRC) patients published so far provides the opportunity to use them as CRC screening markers. We examined the practicability and performance of a low-cost detection approach that relied on culture followed by simplified DNA extraction and PCR in E. coli isolates recovered from 130 CRC patients and 111 controls. Our results showed a statistically significant association between CRC and the presence of colibactin genes clbB and clbN, the cnf gene, and newly, the hemolytic phenotype of E. coli isolates. We also observed a significant increase in the mean number of morphologically distinct E. coli isolates per patient in the CRC cohort compared to controls, indicating that the cyclomodulin-producing E. coli strains may represent potentially preventable harmful newcomers in CRC patients. A colibactin gene assay showed the highest detection rate (45.4%), and males would benefit from the screening more than females. However, because of the high number of false positives, practical use of this marker must be explored. In our opinion, it may serve as an auxiliary marker to increase the specificity and/or sensitivity of the well-established fecal immunochemical test (FIT) in CRC screening.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22001412
- 003
- CZ-PrNML
- 005
- 20220112153601.0
- 007
- ta
- 008
- 220107s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/life11111165 $2 doi
- 035 __
- $a (PubMed)34833041
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Mezerová, Kristýna $u Department of Microbiology, Faculty of Medicine & Dentistry, Palacký University Olomouc, Hněvotínská 3, 775 15 Olomouc, Czech Republic
- 245 10
- $a Cyclomodulins and Hemolysis in E. coli as Potential Low-Cost Non-Invasive Biomarkers for Colorectal Cancer Screening / $c K. Mezerová, L. Starý, P. Zbořil, I. Klementa, M. Stašek, P. Špička, P. Skalický, V. Raclavský
- 520 9_
- $a The frequent occurrence of E. coli positive for cyclomodulins such as colibactin (CLB), the cytotoxic necrotizing factor (CNF), and the cytolethal distending factor (CDT) in colorectal cancer (CRC) patients published so far provides the opportunity to use them as CRC screening markers. We examined the practicability and performance of a low-cost detection approach that relied on culture followed by simplified DNA extraction and PCR in E. coli isolates recovered from 130 CRC patients and 111 controls. Our results showed a statistically significant association between CRC and the presence of colibactin genes clbB and clbN, the cnf gene, and newly, the hemolytic phenotype of E. coli isolates. We also observed a significant increase in the mean number of morphologically distinct E. coli isolates per patient in the CRC cohort compared to controls, indicating that the cyclomodulin-producing E. coli strains may represent potentially preventable harmful newcomers in CRC patients. A colibactin gene assay showed the highest detection rate (45.4%), and males would benefit from the screening more than females. However, because of the high number of false positives, practical use of this marker must be explored. In our opinion, it may serve as an auxiliary marker to increase the specificity and/or sensitivity of the well-established fecal immunochemical test (FIT) in CRC screening.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Starý, Lubomír $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Zbořil, Pavel $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Klementa, Ivo $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Stašek, Martin $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Špička, Petr $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Skalický, Pavel $u First Department of Surgery, University Hospital Olomouc, I. P. Pavlova 6, 779 00 Olomouc, Czech Republic
- 700 1_
- $a Raclavský, Vladislav $u Department of Microbiology, Faculty of Medicine & Dentistry, Palacký University Olomouc, Hněvotínská 3, 775 15 Olomouc, Czech Republic
- 773 0_
- $w MED00186366 $t Life (Basel, Switzerland) $x 2075-1729 $g Roč. 11, č. 11 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34833041 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220107 $b ABA008
- 991 __
- $a 20220112153557 $b ABA008
- 999 __
- $a ind $b bmc $g 1745467 $s 1152559
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 11 $c 11 $e 20211031 $i 2075-1729 $m Life $n Life (Basel) $x MED00186366
- GRA __
- $a IGA_LF_2021_022 $p the Faculty of Medicine & Dentistry, Palacký University Olomouc
- GRA __
- $a DRO 61989592 $p the Ministry of Education, Youth and Sports, Czech Republic
- GRA __
- $a DROFNOl 00098892, NV19-03-00069 $p the Ministry of Health, Czech Republic
- LZP __
- $a Pubmed-20220107